Center for Research in Emerging Infections and Vaccines

描述（由申请人提供）： 该提案是为圣刘易斯大学新的生物医学研究大楼的一部分申请资金，以容纳新兴感染和疫苗研究中心（CREIV）。新的生物医学研究大楼的建设是未来两年内大学的最高优先事项之一，CREIV的设施包括该项目的第一阶段。该申请要求为CREIV提供51，095总平方英尺的装修资金，该大学在疫苗开发，分子生物学，病毒学，免疫学和流行病学方面的专业知识可以扩展。 该中心的重点是将免疫学，微生物学和传染病的基础研究转化为有效的疫苗和治疗方法。该中心将由该大学的疫苗和治疗评估单位，艾滋病毒疫苗评估单位，中西部生物防御卓越研究中心和心脏地带疫苗开发联盟组成。 CREIV的这一创新性新设施将： 1.为培训科学家提供丰富的环境，以满足对利用新技术重新评估旧疫苗（包括旧生物防御疫苗）以提高安全性和有效性的专业知识的迫切需求。 2.为基础和临床研究的研究人员提供最先进的设施，以加强跨学科工作，并导致预防和治疗感染以及开发疫苗的发现。 3.提供生物防御教育计划的接口，如SLU的公共卫生学院生物恐怖主义和新兴感染研究中心。 4.通过加强对免疫系统衰老的理解，增加在服务不足的人群（包括老年人接种疫苗）进行跨学科研究的机会。 5.通过在发病机理和预防研究方面的合作，加快艾滋病毒疫苗的开发。

DESCRIPTION (provided by applicant): This proposal is to request funds for the portion of a new biomedical research building at Saint Louis University to house the Center for Research in Emerging Infections and Vaccines (CREIV). Construction of the new biomedical research building is one of the University's highest priorities within the next two years, and facilities for the CREIV comprise the first phase of this project. This application requests funding for fit-out of 51,095 gross square feet for the CREIV, where the University's proven expertise in vaccine development, molecular biology, virology, immunology, and epidemiology can be expanded. The Center's focus is to translate basic research in immunology, microbiology, and infectious disease into effective vaccines and therapeutics. The Center will be comprised of the University's Vaccine and Treatment Evaluation Unit, HIV Vaccine Evaluation Unit, Midwest Research Center for Excellence in Biodefense, and Heartland Consortium for Vaccine Development. This innovative new facility for the CREIV will: 1. Provide a rich environment for the training of scientists to meet a critical need for expertise in reassessing older vaccines (including older biodefense vaccines) with new technologies to improve safety and efficacy. 2. Provide investigators in basic and clinical research with state-of-the-art facilities to enhance interdisciplinary work and lead to discoveries for the prevention and treatment of infections and the development of vaccines. 3. Provide an interface with educational programs in biodefense, such as SLU's Center for the Study of Bioterrorism and Emerging Infections in the School of Public Health. 4. Improve opportunities for interdisciplinary research in underserved populations (including vaccination of the elderly) through enhanced understanding of the senescence of the immune system. 5. Accelerate HIV vaccine development through collaboration on pathogenesis and prevention research.